Literature DB >> 27098218

Targeted therapy: Generic imatinib - impact on frontline and salvage therapy for CML.

Larry Gorkin1, Hagop Kantarjian2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27098218      PMCID： PMC5450934          DOI： 10.1038/nrclinonc.2016.59

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  4 in total

1.  Are high drug prices for hematologic malignancies justified? A critical analysis.

Authors:  Jagpreet Chhatwal; Michael Mathisen; Hagop Kantarjian
Journal:  Cancer       Date:  2015-06-23       Impact factor: 6.860

2.  Having "Skin in the Game" and Allowing Cross-Border Importation of Drugs to Lower High Prices of Cancer Drugs.

Authors:  Hagop Kantarjian; Michael S Mathisen; Jeffrey H Lipton
Journal:  JAMA Oncol       Date:  2015-09       Impact factor: 31.777

3.  Strategies that delay or prevent the timely availability of affordable generic drugs in the United States.

Authors:  Gregory H Jones; Michael A Carrier; Richard T Silver; Hagop Kantarjian
Journal:  Blood       Date:  2016-01-27       Impact factor: 22.113

4.  Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.

Authors:  William V Padula; Richard A Larson; Stacie B Dusetzina; Jane F Apperley; Rudiger Hehlmann; Michele Baccarani; Ekkehard Eigendorff; Joelle Guilhot; Francois Guilhot; Rudiger Hehlmann; Francois-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Susanne Saussele; Charles A Schiffer; Richard T Silver; Bengt Simonsson; Rena M Conti
Journal:  J Natl Cancer Inst       Date:  2016-03-04       Impact factor: 13.506
  4 in total
  5 in total

Review 1.  Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making.

Authors:  James A Kennedy; Gabriela Hobbs
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

2.  Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.

Authors:  Ya-Chen Tina Shih; Jorge E Cortes; Hagop M Kantarjian
Journal:  Lancet Haematol       Date:  2019-06-14       Impact factor: 18.959

Review 3.  Pharmacological Modulators of Autophagy as a Potential Strategy for the Treatment of COVID-19.

Authors:  Gustavo José da Silva Pereira; Anderson Henrique França Figueredo Leão; Adolfo Garcia Erustes; Ingrid Beatriz de Melo Morais; Talita Aparecida de Moraes Vrechi; Lucas Dos Santos Zamarioli; Cássia Arruda Souza Pereira; Laís de Oliveira Marchioro; Letícia Paulino Sperandio; Ísis Valeska Freire Lins; Mauro Piacentini; Gian Maria Fimia; Patrícia Reckziegel; Soraya Soubhi Smaili; Claudia Bincoletto
Journal:  Int J Mol Sci       Date:  2021-04-15       Impact factor: 5.923

4.  Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia.

Authors:  Hyacinthe Johnson-Ansah; Benjamin Maneglier; Françoise Huguet; Laurence Legros; Martine Escoffre-Barbe; Martine Gardembas; Pascale Cony-Makhoul; Valérie Coiteux; Laurent Sutton; Wajed Abarah; Camille Pouaty; Jean-Michel Pignon; Bachra Choufi; Sorin Visanica; Bénédicte Deau; Laure Morisset; Emilie Cayssials; Mathieu Molimard; Stéphane Bouchet; François-Xavier Mahon; Franck Nicolini; Philippe Aegerter; Jean-Michel Cayuela; Marc Delord; Heriberto Bruzzoni-Giovanelli; Philippe Rousselot
Journal:  Pharmaceutics       Date:  2022-08-12       Impact factor: 6.525

5.  PML-RARA Fusion Transcripts Detectable 8 Months prior to Promyelocytic Blast Crisis in Chronic Myeloid Leukemia.

Authors:  Stephanie Wolanin; Robert K McCall; Mark J Pettenati; Michael W Beaty; Giovanni Insuasti-Beltran; Bayard L Powell; Stacey S O'Neill
Journal:  Case Rep Hematol       Date:  2020-09-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.